Prelude Therapeutics to Join June 2024 Healthcare Conferences

WILMINGTON, Del., June 03, 2024 — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a company specializing in precision oncology at the clinical stage, has announced its participation in two major healthcare conferences happening in June.

Jefferies Global Healthcare Conference 2024
On Thursday, June 6th, at 1:30 p.m. ET, Kris Vaddi, Ph.D., the Chief Executive Officer of Prelude, will engage in a fireside chat. This discussion will be available via a live webcast.

Goldman Sachs 45th Annual Global Healthcare Conference
On Wednesday, June 12th, at 10:40 a.m. ET, Dr. Vaddi is scheduled to deliver a corporate presentation. A live webcast of this presentation will also be accessible.

For those interested in viewing the webcast recordings, they will be archived on Prelude’s website under the Events and Presentations section and will remain available for 90 days.

About Prelude Therapeutics
Prelude Therapeutics is a leading clinical-stage precision oncology firm focused on developing innovative drug candidates that target essential pathways in cancer cells. The company has a diverse drug pipeline of highly differentiated and potentially best-in-class small molecule compounds. These compounds are designed to address clinically validated pathways for cancers that affect specific underserved patient populations.

Currently, the company has three drug candidates in the clinical development phase:
- PRT3789: An intravenously administered, potent, and highly selective SMARCA2 degrader.
- PRT2527: A potent and highly selective CDK9 inhibitor.
- PRT3645: A next-generation CDK4/6 inhibitor.

Additionally, Prelude is working on an orally bioavailable SMARCA2 degrader, PRT7732, which shows strong potential.

Prelude is also involved in a collaboration with AbCellera to discover, develop, and commercialize up to five next-generation antibody drug conjugate (ADC) products. This partnership leverages AbCellera’s advanced antibody discovery and development platform in combination with Prelude's expertise in medicinal chemistry and drug development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!